Immunophotonics Lu Alleruzzo, CEO and Tomas Hode, PhD, CIO, and President have announced a research collaboration with Johnson & Johnson Enterprise Innovation Inc. (JJEI) to explore the use of radiation in conjunction with Immunophotonics’ lead drug candidate, IP-001, as a novel immunotherapy approach for the treatment of solid tumor cancers.

This collaboration agreement represents a compelling opportunity to broaden the potential applications of IP-001 and its underlying technology platform.  Immunophotonics looks forward to seeing this collaboration help further unlock the potential of our novel drug and serve as a natural extension of the emerging field of Interventional Immuno-Oncology™.

Read more: Official Press Release